-
Walsun Biotech Achieves Top ESG Rating, Underscores Commitment to Sustainability
•
Yunnan Walsun Biotech Co., Ltd. has seen its ESG rating upgraded to BBB by MSCI, a significant leap from its previous B rating and a reflection of the company’s industry-leading sustainability practices. This achievement underscores Walsun’s commitment to ESG management, aligning with global investment standards and strategies. Walsun Biotech, known…
-
Novartis’ Cemiplimab Approved in China for Moderate-to-Severe Atopic Dermatitis
•
Novartis (SWX: NOVN, NYSE: NVS)’s Chinese arm has announced that it has received approval from the National Medical Products Administration (NMPA) for its drug candidate, cemiplimab, to be used in the treatment of adults and children aged 12 and over with moderate-to-severe atopic dermatitis (AD). The drug, known as cemiplimab…
-
Innovent Biologics Launches Phase I Clinical Trial for IBR822 Cell Injection Solution in Solid Tumors
•
Innovent Biologics (Hangzhou) Co., Ltd (HKG: 1801, OTCMKTS: IVBXF), a biopharmaceutical company based in China, has announced the successful initiation of a Phase I clinical trial for its proprietary IBR822 cell injection solution at Zhejiang Cancer Hospital. The trial, led by Professor Song Zhengbo from Zhejiang Cancer Hospital, is conducted…
-
Johnson & Johnson’s Tremfya Gains FDA Approval for Ulcerative Colitis Treatment
•
Johnson & Johnson (NYSE: JNJ) announced today that the US Food and Drug Administration (FDA) has granted approval for Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC). With this approval, Tremfya stands out as the sole fully-human, dual-acting monoclonal antibody that not only…
-
Sanofi Secures Global Rights to Radioligand Therapy AlphaMexi in Deal with RadioMedix and Orano Med
•
Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has entered into a significant licensing agreement with US biotechnology firm RadioMedix Inc. and French company Orano Med, securing global rights to a radioligand therapy (RLT). The agreement centers on AlphaMexi (212Pb-DOTAMTATE), a targeted alpha therapy (TAT) that utilizes a…
-
Roche’s Tecentriq Hybreza Becomes First Subcutaneous Anti-PD-(L)1 Immunotherapy in the US
•
Roche (SWX: ROG; OTCMKTS: RHHBY) , a leading Swiss pharmaceutical company, has secured US Food and Drug Administration (FDA) approval for its subcutaneous formulation of the programmed death-ligand 1 (PD-L1) inhibitor, Tecentriq Hybreza (atezolizumab, hyaluronidase). This new formulation has been approved for all 12 adult indications of intravenous Tecentriq, covering…
-
Lilly’s Once-Monthly Atopic Dermatitis Treatment Ebglyss Gets Green Light from FDA
•
Eli Lilly & Co. (NYSE: LLY) has announced that it has received market approval from the US Food and Drug Administration (FDA) for Ebglyss (lebrikizumab), a new treatment for adults and children aged 12 years and over suffering from moderate-to-severe atopic dermatitis (AD). Ebglyss is an interleukin-13 (IL-13) inhibitor that…
-
Roche’s Ocrevus Zunovo Receives FDA Nod as First Twice-Yearly MS Treatment
•
Roche Group (SWX: ROG; OTCMKTS: RHHBY) , a Swiss pharmaceutical giant, has announced that the US Food and Drug Administration (FDA) has granted approval for Ocrevus Zunovo (ocrelizumab, hyaluronidase), marking a significant advancement in the treatment of multiple sclerosis (MS). This new formulation is the first and only twice-per-year treatment…
-
Ascentage Pharma’s Olverembatinib Shows Promise in SDH-Deficient GIST at ESMO Congress
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced the presentation of clinical study results for its drug olverembatinib (HQP1351) at the 2024 European Society of Medical Oncology (ESMO) Congress. The study focused on patients with succinate dehydrogenase-deficient gastrointestinal stromal tumor (GIST), a rare and aggressive form…
-
Fosun Pharma to Acquire Full Stake in Fosun Kite Biotechnology for USD 27 Million
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has disclosed plans to acquire the remaining 50% stake in its joint venture, Fosun Kite Biotechnology Co., Ltd, from Gilead’s subsidiary Kite Pharma for USD 27 million. This transaction will see Fosun Pharma assume full ownership of Fosun Kite, with…
-
Jiangsu Hengrui’s HER2-Targeted ADC SHR-A1811 Receives Priority Review from China’s NMPA
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced that the National Medical Products Administration (NMPA) has accepted its market filing for trastuzumab rezetecan (SHR-A1811), an antibody-drug conjugate (ADC) targeting HER2, with priority review status. The drug is intended for the treatment of adult…
-
Hangzhou-Based Ophthalmic Device Maker MDCO Secures RMB 200 Million in Series B Funding
•
MDCO, an ophthalmic medical device company headquartered in Hangzhou, has reportedly secured nearly RMB 200 million in a Series B financing round. The funding was led by Hangzhou Qiantang Heda Bio-medical Investment Fund, Sunland Capital, and existing investor Decheng Capital. The capital raised will be allocated to bolster the company’s…
-
Beijing Wantai Biological and Fujian Provincial CDC Collaborate on Vaccine Development and Public Health Initiatives
•
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading biopharmaceutical company based in China, has entered into a strategic partnership with the Fujian Provincial Center for Disease Control and Prevention (FJCDC). This collaboration will focus on enhancing efforts in pathogen detection technology, vaccine development, clinical research, scientific outreach,…
-
MGI Tech and Haihe Laboratory Deepen Collaboration with Introduction of CycloneSEQ-WT02
•
MGI Tech Co., Ltd, a prominent gene sequencing company based in China, has disclosed a previous collaboration with the Haihe Laboratory of Cell Ecosystem under the China Academy of Medical Sciences, which commenced under the ‘SEQ ALL’ multi-omics initiative. This partnership initially led to the establishment of a multi-omics DCS…
-
MGI Tech and Sequanta Technologies Launch Advanced DCS Lab to Accelerate Omics Research
•
MGI Tech Co., Ltd, a leading gene sequencing specialist based in China, has entered into a strategic partnership with fellow Chinese firm Sequanta Technologies Co., Ltd, marking a significant step with the establishment of the “Sequanta-MGI DCS Lab.” The DCS Lab is a state-of-the-art facility equipped with cutting-edge technology, including…
-
Moderna Inc. Announces Cost-Cutting Measures and Pipeline Realignment
•
Moderna Inc. (NASDAQ: MRNA), a leading mRNA technology company based in the U.S., has announced a strategic realignment during its investor R&D day, reflecting a broader trend among multinational corporations (MNCs) to streamline operations. The company has committed to a program that includes cost-cutting measures and a reprioritization of its…
-
Sino Biological and BioGeometry Broaden Partnership to Advance AI-Driven Drug Discovery
•
Sino Biological (SHE: 301047), a leading biotech company in China, and BioGeometry have announced an expansion of their partnership to harness generative artificial intelligence (AI) for drug discovery. While the financial details of the deal remain undisclosed, the collaboration aims to combine Sino Bio’s advanced protein expression and wet-lab expertise…
-
Johnson & Johnson Submits Second NDA for Nipocalimab to Treat Generalized Myasthenia Gravis
•
Johnson & Johnson (NYSE: JNJ), a leading healthcare company based in the U.S., has reported a second New Drug Application (NDA) filing for its FcRn blocker, nipocalimab. The company has submitted the application to the European Medicines Agency (EMA) for the treatment of adults with generalized myasthenia gravis (gMG) who…
-
Keymed Biosciences’ IL-4Rα mAb Stapokibart Receives NMPA Approval for Atopic Dermatitis Treatment
•
Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has announced that the National Medical Products Administration (NMPA) has approved a market filing for its IL-4Rα monoclonal antibody (mAb) drug candidate, stapokibart (CM310), for the treatment of moderate to severe atopic dermatitis (AD). This marks a significant milestone…
-
South Korea’s MFDS Aims to Slash Drug Approval Times with New Innovation Plan
•
South Korea’s Ministry of Food and Drug Safety (MFDS) has unveiled an ambitious plan to expedite its drug review and approval process, as reported in a recent press briefing. The “New Drug Approval Innovation Plan” targets a significant reduction in the timeline for novel drug reviews to under 300 days,…
